ID   VU-SCC-1365
AC   CVCL_XX19
SY   VU1365; VU-1365
DR   cancercelllines; CVCL_XX19
DR   IARC_TP53; 21671
DR   Wikidata; Q98134588
RX   PubMed=15735012;
RX   PubMed=23613873;
RX   PubMed=25609062;
RX   PubMed=26122845;
RX   PubMed=31541927;
RX   PubMed=36912284;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:1509; CASP8; Simple; p.Arg432Ter (c.1294C>T); Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:7133; KMT2D; Simple; p.Glu838Lys (c.2512G>A); Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (PubMed=15735012; PubMed=23613873; PubMed=31541927).
CC   Omics: Genome sequenced (low read coverage).
ST   Source(s): PubMed=36912284
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9
ST   D5S818: 8
ST   D7S820: 8
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C4040; Buccal mucosa squamous cell carcinoma
DI   NCIt; C125702; Fanconi anemia, complementation group A
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
DI   ORDO; Orphanet_84; Fanconi anemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=15735012; DOI=10.1158/0008-5472.CAN-04-3665;
RA   van Zeeburg H.J.T., Snijders P.J.F., Pals G., Hermsen M.A.J.A.,
RA   Rooimans M.A., Bagby G., Soulier J., Gluckman E., Wennerberg J.,
RA   Leemans C.R., Joenje H., Brakenhoff R.H.;
RT   "Generation and molecular characterization of head and neck squamous
RT   cell lines of Fanconi anemia patients.";
RL   Cancer Res. 65:1271-1276(2005).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555; PMCID=PMC3629194;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=25609062; DOI=10.1158/1078-0432.CCR-14-2616; PMCID=PMC4401632;
RA   Lombardi A.J., Hoskins E.E., Foglesong G.D., Wikenheiser-Brokamp K.A.,
RA   Wiesmuller L., Hanenberg H., Andreassen P.R., Jacobs A.J., Olson S.B.,
RA   Keeble W.W., Hays L.E., Wells S.I.;
RT   "Acquisition of relative interstrand crosslinker resistance and PARP
RT   inhibitor sensitivity in Fanconi anemia head and neck cancers.";
RL   Clin. Cancer Res. 21:1962-1972(2015).
//
RX   PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528;
RA   Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B.,
RA   Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A.,
RA   Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.;
RT   "Defects in the Fanconi anemia pathway and chromatid cohesion in head
RT   and neck cancer.";
RL   Cancer Res. 75:3543-3553(2015).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004; PMCID=PMC7372097;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//
RX   PubMed=36912284; DOI=10.1002/ijc.34506;
RA   Nguyen H.T., Tang W.-L., Webster A.L.H., Whiteaker J.R., Chandler C.M.,
RA   Errazquin Ciudad R., Roohollahi K., Fritzke M., Hoskins E.E., Jonlin E.C.,
RA   Wakefield L., Sullivan L.B., Chen E.Y., Dorsman J.C., Brakenhoff R.H.,
RA   Paulovich A.G., Grompe M., Garcia-Escudero R., Wells S.I.,
RA   Smogorzewska A., Monnat R.J. Jr.;
RT   "Fanconi anemia-isogenic head and neck cancer cell line pairs: a basic
RT   and translational science resource.";
RL   Int. J. Cancer 153:183-196(2023).
//